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We report an adult female patient who presented with sacral radiculopathy as incapacitating dysthesias following primary genital
herpes simplex, which later recurred. Despite use of systemic antiviral treatment, the painful syndrome in our patient persisted.
The success in treatment was seen only after the addition of amitriptyline hydrochloride. The case is being presented here for its
rare manifestation and novel use of amitriptyline hydrochloride.
1.CasePresentation
We present the case of a 64-year-old female teacher who
presented to the sexual health clinic in Newcastle, Australia.
Six weeks previously, the patient had attended her
primary care doctor (PCD) with dysuria and was treated
for a urinary tract infection; however, symptoms persisted.
Several days later she noticed acute onset of bilateral vulval
blisters. She was clinically diagnosed with genital herpes and
commenced on valacyclovir 500mg bd for one week. The
blisters resolved within ﬁve days; however, she developed
burning and exquisite sensitivity to touch in both inner
thighs and in the left buttockextending down the left leg and
including the sole of the left foot and toes. She found that
at times, she was unable to walk and sit. She returned to her
PCD who continued valacyclovir for another week; however,
the burning persisted.
On presentation to the sexual health clinic, the patient
had completed six weeks of valacyclovir 500mg bd with
minimal improvement. Vulval ulcers had not recurred. The
patient denied any other signs or symptoms and gave no
history of prodromal symptoms. She was in a monogamous
sexual relationship of four months duration with a male
partner who was taking suppressive treatment for herpes
simplex type 2 (HSV2) genital infection. She was unable
to comment regarding her partners’ adherence with this
treatment. They did not use condoms consistently. Her
previous sexual partner, over 12 months previously, was her
husband for 20 years. The patient had no prior history of
genital herpes, and her PCD was not able to be contacted
to conﬁrm swab collection or diagnosis. General history
was unremarkable; she had a total hysterectomy at age 40
with sparing of the ovaries and denied history of shingles;
however,she had chickenpoxas a child.Shehadcommenced
escitalopram oxalate 10mg/d at the time of her marriage
breakup four months previously.
Examination of the genital area was unremarkable.
Neurological examination of the lower limbs revealed hyper-
aesthesia in dermatomes S1, S2, and S3 on the left side.
There was no other sensory abnormality or motor deﬁcit
found.Aherpesviruspolymerasechainreaction(PCR)swab
t e s ta tt h es i t eo fh e a l e dv u l v a lb l i s t e r sw a sn e g a t i v ef o r
both varicella zoster virus and herpes simplex virus (HSV).
First catch urine PCR was negative for Neisseria gonorrhoea
and Chlamydia trachomatis. The patient declined serology
for herpes simplex infection. Pain management options
were discussed including low-dose tricyclic antidepressants,
gabapentin, and simple analgesics.
The patient returned four days later and was started
on amitriptyline hydrochloride 10mg nocte increased to
20mg nocte after two weeks. Potential interaction with
escitalopram oxalate was discussed, and the patient was
advised that this was low. The pain resolved after four weeks
of amitriptyline hydrochloride at 20mg, and the treatment
was ceased.2 Dermatology Research and Practice
The patient experienced a further episode of genital
blisters three months later and self-medicated with topical
acyclovir. Vulval lesions resolved within two days; however,
she again experienced residual neuropathic pain in the same
distribution. This episode was milder than the ﬁrst and
responded after three weeks of amitriptyline hydrochloride
treatment.
Genital herpes is commonly due to HSV2; however,
an increasing proportion of new infections are caused by
HSV1, primarily responsible for orolabial infection. In fact,
either HSV1 or 2 may infect genital or extra genital sites.
Although unconﬁrmed microbiologically, this patient gives
a classic history of ﬁrst episode genital herpes complicated
by sacral radiculopathy manifesting as hyperaesthesia. Vulval
PCRswab takenat ourclinicwas negative. This was collected
despitecompletehealingoflesions,asPCRtestingmaydetect
asymptomatic viral shedding although sensitivity is low. As
the patient was still experiencing hyeraesthesia, and this was
the ﬁrst episode infection, it was postulated that she may
have continued to shed virus. However, given the previous
few weeks of antiviral medications, this test was predictably
negative.
At 64 years, this patient is signiﬁcantly older than most
patients presenting to health services with ﬁrst episode
herpes, the median age being mid 20s [1, 2]. Her low-risk
sexual history may be one explanation. Given her current
partner is HSV2 positive, this is most likely the causative
virus. Once infected, the virus establishes latency in the
dorsal root ganglion, asymptomatically shedding virus, and
reactivating in the form of recurrent lesions from time to
time. Studies have shown that HSV2 recurs more frequently
thanHSV1,andalthoughsuppressiveantiviraltreatmentwill
decrease frequency of recurrent infection and asymptomatic
shedding, it doesnot preventit. Furthermore, antiviral treat-
menthasshowntodecreaseratesofpartnertransmission [3].
Similarly, condoms, even if used consistently are not 100%
reliable although they oﬀer good protection [4]. Condoms
were not used consistently by our patient.
First-episode infections are associated with more exten-
sive disease, systemic symptoms, and greater viral shedding
than recurrences [5]. Patients experiencing ﬁrst episode gen-
ital herpes classically present with pain, itching, and burn-
ing, with 80% of women reporting dysuria [6]. Although
systemic symptoms are present in 70% of women, they were
absent in this case.
Neurological complications are typically associated with
primary infection; however, unlike aseptic meningitis and
accompanying meningism which occurs commonly in an
estimated 20%–30% of individuals, autonomic nervous
system dysfunction and sacral radiculopathy is less common,
estimated in 1%-2% of cases [6, 7]. Peripheral neurological
complications associated with autonomic nervous system
involvement have been described in the literature and vary
enormouslyfrom paraesthesias, hyperaesthesias, and dysthe-
sias to urinary retention and constipation. Transverse myeli-
tis has also been reported, and in some cases it has been fatal
[8].Myelitis occurringtogetherwithautonomicnervoussys-
tem involvement presents as urinary retention as a result of
sacral myeloradiculitis and is known as Elsberg syndrome [9].
Whilst most case reports are in patients diagnosed with
HSV2, peripheral neurological complications may occur
with either HSV type [10, 11]. These usually resolve grad-
ually over days to weeks, but as demonstrated in this case,
symptoms can persist for months [5, 12] .W h i l ec a s er e p o r t s
have suggested that eﬀective antiviral medication provides
moderate relief and speeds recovery, we did not observe a
signiﬁcant eﬀect of pain moderation in our patient [13, 14].
Neuropathic pain commonly occurs with recurrences in
the prodromal phase of infection. Reactivation of infection
results in neuropathic symptoms at the potential lesions
site or along the distribution of the infected ganglia. It
is uncommon to experience neurological complications of
recurrent infection although these have been described [15].
However, there are few reports describing an association of
herpes simplex infection and hyperaesthesia.
Neurological complications are more frequently seen
with varicella zoster virus (VZV), another alpha virus of the
herpesviridae family. Although there are various deﬁnitions
of post herpetic neuralgia (PHN), it is estimated that 3%–
7% of patients have pain persisting for more than three
months following shingles rash, 2%–5% after one year [16–
19]. The pathogenesis of PHN and similar neuropathic pain
syndromes is due to inﬂammation, neuronal damage, and
dysregulation of the immune system; although, the actual
mechanism remains unclear. Studies have shown that the
incidence and duration of PHN are associated with age [20].
Age may have been a signiﬁcant factor in our 64-year-old
patient. We considered the diagnosis of PHN complicating
vulval zoster in the patient. Unlike HSV, however, VZV
reactivations are rare in immunocompetent individuals due
to the diﬀerences in molecular mechanisms controlling
latency of these viruses [21].
Patient clinical and medical history, together with the
absence of lesions in the orolabial area and elsewhere,
helped to exclude other diﬀerential diagnoses such as drug
eruptions (ﬁxed drug eruptions, erythema multiforme),
pemphigus, the pemphigoid group of diseases, insect bites,
and infestations. The recurrent nature patient symptoms,
typical of genital herpes, helped to conﬁrm this.
In this case, valacyclovir had minimal eﬀectonneurolog-
ical pain despite prompt resolution of vulval lesions. Antivi-
ral medication has been shown to speed healing of the VZV
rash and reduce viral shedding and new lesion formation. As
a result of reduced viral replication, antiviral treatment may
limit initial neuronal damage and inﬂammation, thereby
ameliorating neuropathic complications. Antiviral inﬂuence
on clinical course is unclear in this case. Valacyclovir was
commenced approximately one week following symptom
onset (i.e., at least one week of viral replication). We are
unable to speculate as to the inﬂuence of this medication.
As hyperaesthesia prevented the patient from working
we elected to treat with low-dose tricyclic antidepressants
(TCAs). TCAs, at low doses, have shown to be eﬀective in
treatment of neuropathic pain by blocking the reuptake of
monoamine neurotransmitters released by descending axons
from the brainstem, thereby augmenting catecholamine
neurotransmission. Experience is mostly with amitriptyline
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in PHN. Used in combination with antiviral medication,
low-dose amitriptyline hydrochloride has been shown to
signiﬁcantly decrease duration of PHN in patients >60
years [22]. While TCAs use in PHN is well documented,
there are no documented cases we could ﬁnd for its use
in hyperaesthesia complicating genital herpes. Although
the patient reported an improvement in symptoms, it
is unknown whether use of amitriptyline hydrochloride
aﬀected the initial clinical course; however, prompt response
to recurrent hyperaesthesia is more convincing. Certainly,
with treatment, she was able to return to work.
The major weakness in this case is that we were unable
to make a deﬁnitive laboratory diagnosis. However, the
classic and recurrent nature of the lesions, history of deﬁnite
exposure to a HSV2 positive source, and prompt lesion
healing with the use of antiviral medication lead us to
stronglybelievethattheclinicaldiagnosiswasherpessimplex
infection in both the episodes.
In conclusion, sacral radiculopathy may present as
troublesome hyperesthesia following primary genital herpes
simplex infection. Amitriptyline may oﬀer a therapeutic
option in such patients if systemic antiviral therapy is
inadequate or ineﬀective.
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